Neoadjuvant treatment of renal cell cancer

Scottish Cancer Network: Clinical Management Pathways
NHS National Services Scotland
Scottish Cancer Network logo

There is insufficient evidence to recommend routine use of SACT in the neoadjuvant setting, however, this can be considered on a case-by-case basis following local SACT governance processes, as use in this setting is off-license.

Editorial Information

Last reviewed: 15/12/2025

Next review date: 15/12/2028

Author(s): Balaji Venugopal and Rhona McMenemin, on behalf of the Renal Cell Cancer SACT group.

Version: 1.0

Reviewer name(s): Balaji Venugopal, Rhona McMenemin.